{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:06:34Z","timestamp":1761919594708},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.autrev.2012.03.010","type":"journal-article","created":{"date-parts":[[2012,7,25]],"date-time":"2012-07-25T21:45:54Z","timestamp":1343252754000},"page":"337-339","source":"Crossref","is-referenced-by-count":35,"title":["Drug induced autoimmune hepatitis and TNF-\u03b1 blocking agents: Is there a real relationship?"],"prefix":"10.1016","volume":"12","author":[{"given":"Cumali","family":"Efe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2012.03.010_bb0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.autrev.2009.01.005","article-title":"Predicting response to anti-TNF treatment in rheumatoid arthritis patients","volume":"8","author":"Atzeni","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.03.010_bb0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","article-title":"Serious infections during anti-TNF\u03b1 treatment in rheumatoid arthritis patients","volume":"8","author":"Favalli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.03.010_bb0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.04.010","article-title":"Anti-TNF therapy: safety aspects of taking the risk","volume":"10","author":"Rosenblum","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.03.010_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2004.09.004","article-title":"TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma","volume":"4","author":"Sarzi-Puttini","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.03.010_bb0150","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s10620-009-0996-9","article-title":"The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases:report of three cases and review of the literature","volume":"55","author":"Efe","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2012.03.010_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.03.010_bb0040","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10067-008-0885-1","article-title":"A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis","volume":"27","author":"Harada","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.crohns.2010.12.007","article-title":"Autoimmune hepatitis during infliximab therapy for Crohn's disease: a case report","volume":"5","author":"Doyle","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2012.03.010_bb0050","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2009.02.029","article-title":"Autoimmune hepatitis in two psoriasis patients treated with inflixmab","volume":"63","author":"Goujon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0055","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0060","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/hep.23834","article-title":"Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor \u03b1 agents","volume":"52","author":"Efe","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2012.03.010_bb0065","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-doublestranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2012.03.010_bb0070","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/ard.2004.030262","article-title":"Blockade of tumour necrosis factor a significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis","volume":"64","author":"Yazdani-Biuki","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2012.03.010_bb0075","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2012.03.010_bb0085","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis vs. drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2012.03.010_bb0090","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2011.02.024","article-title":"Drug induced liver injury and its relationship to autoimmune hepatitis","volume":"55","author":"Weiler-Normann","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0095","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","article-title":"Drug-induced autoimmune-like hepatitis","volume":"56","author":"Czaja","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.autrev.2012.03.010_bb0100","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bjornsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2012.03.010_bb0105","first-page":"13","article-title":"The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases\u20142008","volume":"10","author":"Shoenfeld","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2012.03.010_bb0110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.autrev.2007.11.021","article-title":"The mosaic of autoimmunity","volume":"7","author":"Gershwin","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2012.03.010_bb0115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bpg.2011.09.011","article-title":"Autoimmune hepatitis in special patient populations","volume":"25","author":"Czaja","year":"2011","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis","volume":"354","author":"Krawitt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2012.03.010_bb0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/ar3085","article-title":"Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes","volume":"12","author":"Quintin","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"24 Suppl. 1","key":"10.1016\/j.autrev.2012.03.010_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11586210-000000000-00000","article-title":"Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab","volume":"14","author":"Cravo","year":"2010","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2012.03.010_bb0135","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10067-009-1179-y","article-title":"Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept","volume":"28","author":"Carlsen","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0140","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MCG.0b013e3181a745e7","article-title":"Adalimumab-induced autoimmune hepatitis","volume":"44","author":"Adar","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.autrev.2012.03.010_bb0145","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/RHU.0b013e318188b1df","article-title":"Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept","volume":"14","author":"Fathalla","year":"2008","journal-title":"J Clin Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997212001450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T17:28:16Z","timestamp":1542821296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997212001450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1568997212001450"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2012.03.010","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}